

# BOTULINUM TOXIN: PROFILE OF USE AND FINANCIAL ANALYSIS IN A SPANISH HOSPITAL

JA. Morales-Molina\*, J. Urda-Romacho, A. Martos-Rosa, J. Fernández-Martín, A. Fayet-Pérez, D. González-Vaquero, M. Castro-Vida, P. Acosta-Robles. Hosp. Poniente, Pharmacy Depart. El Ejido, Spain. joseantonio.morales@ephpo.es\*

## ❖ OBJECTIVES

Our objective was evaluate the profile of botulinum toxin (BT) use in the hospital, as well as the saving due to the manufacture of prefilled syringes by the Pharmacy Department.

## ❖ MATERIAL AND METHODS

Retrospective study (Jan-Dic 2013). Data collected: IU consumed of BT, doses, Medical Department, number of patients, indication and cost. The vial of BT (100 IU) was reconstituted with a sterile saline 0.9% (Cabinet of Horizontal Laminar Flow). The reconstituted solution was stable for 4-24 hours at 2-8°C<sup>1,2</sup>. After reconstitution were prepared and they conditioned the pre-filled syringes with the exact doses requested. After the processing, the remaining material was discarded in appropriate container.

## ❖ RESULTS

### Profile of toxinum botulinum (BT) use in the hospital

<b>BT manufactured (IU)</b>	<b>11,615 - 259 patients (682 doses)</b>
<b>Consumption/ Medical Department (IU)</b>	
Pain Unit	<b>4,208</b>
General Surgery	<b>3,074</b>
Rehabilitation	1,900
Others	2,433
<b>Doses more frequently used</b>	
General Surgery (7 IU/ 0.21mL)	<b>392</b>
Pain Unit (75 IU or 100 IU/ 2mL)	31 units and 19 units, respectively
Ophthalmology (5 IU/ 0.15mL)	48
<b>Use of syringes pre-filled/ Medical Department</b>	
General Surgery	<b>400</b>
Ophthalmology	<b>135</b>
Pain Unit	75
Others	72
<b>Cost of BT</b>	<b>28,482.5 euros</b>
<b>Saving/year estimate (direct cost)</b>	<b>12,729.6 euros (- 45%)</b>

The 80% of BT was use in blepharospasm and focal spasticity. The manufactured of pre-filled syringes in Pharmacy Department represented a saving of 81 vials.

## ❖ DISCUSSION AND CONCLUSIONS

The pain Unit and Surgery General presented the higher consumption of BT. The manufactured of pre-filled syringes by the Pharmacy Department allowed us to optimize the consumption of this drug, achieve a considerable cost savings as well as ensure the sterility.

## ❖ REFERENCES

1. Xeomin®. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Referrals\\_document/Xeomin\\_29/WC500008796.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Xeomin_29/WC500008796.pdf).
2. Botox®. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Referrals\\_document/Botox\\_29/WC500010942.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Botox_29/WC500010942.pdf).